Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

a0FVy000005syp7MAA - ESMO Asia 2025 Mini Oral: BREAKWATER East Asian Subset Analysis

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

First-line (1L) Encorafenib + Cetuximab + mFOLFOX6 in East Asian Patients with BRAF V600E-mutant Metastatic Colorectal Cancer (mCRC): Results From The Phase 3 BREAKWATER Study

Scientific presentation
Scientific presentation mobile

Web preview is not available

Try directly downloading the file.